



Principales sources et références



Qu'est-ce que le cancer ?	2
Mécanismes de développement d'un cancer	2
P53	2
Réparation de l'ADN	2
Traitements des cancers	2
Quels sont les facteurs déclencheurs et aggravants des cancers ?	3
Habitudes alimentaires, toxiques et cancers	3
Stress oxydant et cancers	3
Inflammation et cancers	4
Hormone de croissance et cancers	4
Surpoids, Obésité et cancers.....	4
Viande, produits laitiers et cancers.....	5
Sucres et cancers	5
Sel et cancers	5
Acides gras saturés (AGS), Acides gras Trans et cancers.....	6
Quelles sont les pistes de solutions ? Zoom sur l'alimentation et nutriments	7
Végétaux et cancers.....	7
Algues, champignons et cancers.....	8
Polyphénols et cancers	9
Thé, catéchines et cancers.....	9
Curcuma, Curcumine et cancers	10
Polyphénols de grenade et cancers	11
Resvératrol et cancers	11
Caroténoïdes et cancers	11
Oméga 3 et cancers	12
Huile d'olive et cancers	13
Fibres et cancers	14
Lignanes, lin et cancers	14
Phytoestrogènes de soja et cancers.....	14
Nutriments et cancers.....	15
Vitamine C et cancers	15
Magnésium et cancers	15
Zinc et cancers	15
Folates et cancers	15
Vitamine D et cancers	16
Vitamine K2 et cancers	16
Microbiote et cancers	17
Quelles sont les pistes de solutions ? Zoom sur les bonnes pratiques	17
Le jeûne dans le traitement des cancers.....	17
Sarcopénie et cancers	18
Les troubles du sommeil, la mélatonine et cancers.....	18
Stress et cancers	18
Exercices/Activités physiques et cancers.....	18
Quelques Contre-indications	18

Qu'est-ce que le cancer ?

Mécanismes de développement d'un cancer

1. Cancer Prevention Overview (PDQ®). Patient Version. PDQ Screening and Prevention Editorial Board, Published March 8, 2019: <https://www.ncbi.nlm.nih.gov/books/NBK65987/> Consulté pour la dernière fois en octobre 2019
2. Chapter 3: Mechanisms of carcinogenesis – IARC - International Agency for Research on Cancer (OMS). [Mechanisms of Carcinogenesis - IARC Publications](#) Consulté pour la dernière fois en octobre 2019
3. James E Talmadge et al. AACR Centennial Series : The Biology of Cancer Metastasis: Historical Perspective. *Cancer Res*, 2010, 70 (14): 5649–5669
4. Tracey A et al. Cancer Invasion and Metastasis : Molecular and Cellular Perspective, in *Metastatic Cancer: Clinical and Biological Perspectives* edited by Rahul Jandial - Madame Curie Bioscience Database, www.ncbi.nlm.nih.gov/books/NBK164700/

P53

5. Chakraborty A et al. Guarding the 'translation apparatus': Defective ribosome biogenesis and the p53 signaling pathway. *Wiley interdisciplinary reviews*, 2011, RNA. 2. 507-22
6. Hafner A et al. The multiple mechanisms that regulate p53 activity and cell fate. *Nature Reviews – Molecular Cell Biology*, 2019, volume 20
7. Haronikova L et al. The p53 mRNA: an integral part of the cellular stress Response. *Nucleic Acids Research*, 2019, Vol. 47, No. 7 3257–3271
8. Li Y et al. Functional Diversity of p53 in Human and Wild Animals. *Frontiers in Endocrinology*, 2019, 10:152.

Réparation de l'ADN

9. Astley SB et al. Evidence that dietary supplementation with carotenoids and carotenoid-rich foods modulates the DNA damage: repair balance in human lymphocytes. *Br J Nutr*, 2004, 91
10. Berger NA, Sikorski GW. Nicotinamide stimulates repair of DNA damage in human lymphocytes. *Biochem Biophys Res Commun*, 1980, 95 (1) : 67-72
11. Chambon P et al. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. *Biochem Biophys Res Commun*, 1963, 11 : 39–43
12. Chen L et al. Nicotinamide adenine dinucleotide based therapeutics. *Curr Med Chem*, 2008, 15 (7) : 650-70
13. Collins AR et al. Effects of micronutrients on DNA repair. *Eur J Nutr*, 2012, 51 (3) : 261-79
14. Collins, AR et al. Nutritional modulation of DNA repair in a human intervention study. *Carcinogenesis*, 2003, 24, 511-515.
15. Houtkooper RH et al. The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways. *Endocr Rev*, 2010, 31 (2) : 194–223
16. Kirkland JB. Niacin requirements for genomic stability. *Mutat Res*, 2011 Nov 28
17. Masutani M et al. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. *Cell Mol Life Sci*, 2005,62 (7-8) : 769-83
18. Ramos AA et al. Antigenotoxic effects of quercetin, rutin and ursolic acid on HepG2 cells : evaluation by the comet assay. *Toxicol Lett*, 2008, 177, 66-73
19. Ramos AA et al. Polyphenolic compounds from *Salvia* species protect cellular DNA from oxidation and stimulate DNA repair in cultured human cells. *J Agric Food Chem*, 2010, 58, 7465-7471
20. Ramos AA et al. Protective effects of ursolic acid and luteolin against oxidative DNA damage include enhancement of DNA repair in Caco-2 cells. *Mutat Res*, 2010, 692, 6-11
21. Weitberg AB. Effect of nicotinic acid supplementation in vivo on oxygen radical-induced genetic damage in human lymphocytes. *Mutat Res*, 1989, 216 (4) : 197-201

Traitements des cancers

22. Fondation contre le cancer : https://www.cancer.be/le-cancer/traitements-du-cancer?gclid=EAlaIqobChMllpWMvrf_4AIVz4CfCh09Ygm2EAAYASAAEgl_YPD_BwE Consulté pour la dernière fois en octobre 2019
23. Kaufman HL et al. The promise of Immuno-oncology: implications for defining the value of cancer treatment. *J Immunother Cancer*, 2019; 7: 129.
24. Li Y and Sun R. Tumor immunotherapy: New aspects of natural killer cells. *Chin J Cancer Res*, 2018 Apr;30(2):173-196

Quels sont les facteurs déclencheurs et aggravants des cancers ?

Habitudes alimentaires, toxiques et cancers

25. <https://www.cancer.gov/about-cancer/causes-prevention/risk> Consulté pour la dernière fois en octobre 2019
26. Ames BN et al. Are vitamin and mineral deficiencies a major cancer risk? *National Review cancer*, 2002 Sep 2(9):694-704
27. Anand P et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharmaceutical Research* 2008, Sept 25(9)2097-116
28. De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol*, 2019 January 14; 25(2): 151-162.
29. Fiolet T et al. Consumption of ultra-processed foods and cancer risk : results from NutriNet-Santé prospective cohort. *BMJ*, 2018 ; 360 :k322
30. Hogervorst JG et al. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2007, 16 (11) : 2304-13
31. Koutros S et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Res*, 2009, 1 ; 69 (5) : 1877-84
32. Lee HW et al. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. *Oncotarget*, 2014, 5 (11) : 3526–3540
33. Maisonneuve P et al. Risk factors for pancreatic cancer : a summary review of meta-analytical studies. *Int J Epidemiol*, 2014 Dec 14
34. Menke A et al. Cadmium Levels in Urine and Mortality among U.S. Adults. *Environ Health Perspect*, 2009, 117 (2) : 190–196
35. Moutapam D. Cancer du sein : comment le prévenir par la nutrition, *Editions Beaudelaire*
36. Niedzwiecki A et al. Micronutrient synergy - a new tool in effective control of metastasis and other key mechanisms of cancer. *Cancer Metastasis Rev.*, 2010 Sep ; 29(3) :529-42
37. Pariza M. Mutagens and carcinogens in the diet, Wiley-Liss, New York, 1990 Sugimura T, Carcinogenicity of mutagenic heterocyclic amines formed in the cooking process. *Mutation Research*, 1985, 150, 33-41
38. Pelucchi C et al. Exposure to acrylamide and human cancer - a review and meta-analysis of epidemiologic studies. *Ann Oncol*, 2011, 22 (7) : 1487-99
39. Pelucchi C et al. Dietary acrylamide and cancer risk : an updated meta-analysis. *Int J Cancer*, 2014 Nov 18
40. Stott-Miller M et al. Consumption of deep-fried foods and risk of prostate cancer. *Prostate*, 2013, 73 (9): 960–969.
41. Tsai HJ, Chang JS. Environmental Risk Factors of Pancreatic Cancer. *J Clin Med*. 2019 Sep 10;8(9). pii: E1427
42. Willet W.C. Diet and Cancer. *Oncologist*, 2000, 5:393-404
43. Zheng W et al. Well-done Meat Intake, Heterocyclic Amine Exposure, and Cancer Risk. *Nutr Cancer*, 2009, 61 (4) : 437–446
44. <https://fr.wikipedia.org/wiki/Acrylamide>

Stress oxydant et cancers

45. Anetor JI. Industrialization and the increasing risk of genome instability in developing countries: nutrigenomics as a promising antidote. *Afr J Med Med Sci*, 2010; 39 Suppl : 7-20
46. Bitorina AV et al . Low profile high value target: The role of OxLDL in cancer. *Biochim Biophys Acta Mol Cell Biol Lipids*, 2019 Aug 31:158518
47. Chen C et al. Effects of Chronic and Acute Ozone Exposure on Lipid Peroxidation and Antioxidant Capacity in Healthy Young Adults. *Environ Health Perspect*, 2007, 115(12): 1732–1737
48. Di Domenico M et al. The Role of Oxidative Stress and Hormones in Controlling Obesity. *Front Endocrinol (Lausanne)*, 2019 Aug 13;10:540
49. Dossus L et al. Active and passive cigarette smoking and breast cancer risk: Results from the EPIC cohort. *Int J Cancer*, 2014, 134 (8):1871-88
50. Khurana VG et al. Cell phones and brain tumors: a review including the long-term epidemiologic data. *Surg Neurol*, 2009, 72 (3) 205-14
51. Konstantin Salnikow et al. Genetic and Epigenetic Mechanisms in Metal Carcinogenesis and Cocarcinogenesis : Nickel, Arsenic and Chromium. *Chem Res Toxicol*, 2008, 21 (1) : 28–44
52. Ma E et al. Dietary antioxidant micronutrients and all-cause mortality : the Japan collaborative cohort study for evaluation of cancer risk. *J Epidemiol*, 2018 May 2
53. Mohr SB et al. Are low ultraviolet B and high animal protein intake associated with risk of renal cancer? *Int J Cancer*, 2006 Dec 1; 119(11): 2705–2709.
54. Rapports ANSES Radiofréquences et Santé, 2013 - www.anses.fr/fr/documents/AP2011sa0150Ra.pdf
55. Ristow M et al. Oxidative metabolism in cancer growth. *Curr Opin Clin Nutr Metab Care*, 2006, 9 (4) : 339-45
56. Sakanyan V. Reactive Chemicals and Electrophilic Stress in Cancer: A Minireview. *High Throughput*, 2018 Apr 27;7(2)
57. Valavanidis A et al. 8-hydroxy-2'-deoxyguanosine (8-OHdG) : a critical biomarker of oxidative stress and carcinogenesis. *J Environ Sci Health C Environ Carcino Ecotoxicol Rev*, 2009, 27(2):120-39
58. Winter M et al. Prevalence of risk factors for breast cancer in German airline cabin crew: a cross-sectional study. *J Occup Med Toxicol*, 2014, 9:27

Inflammation et cancers

59. da Cruz BO et al. Nutritional strategies to modulate inflammation pathways via regulation of peroxisome proliferator-activated receptor β/δ . *Nutr Rev*, 2019 Oct 4. pii: nuz058
60. Fowler ME et al. Meta-analysis of the association between dietary inflammatory index (DII) and cancer outcomes. *Int J Cancer.*, 2017, 141 (11): 2215-2227
61. Grant WB et al. An ecological study of cancer mortality rates including indices for dietary iron and zinc. *Anticancer Res*, 2008, 28 (3B): 1955-63
62. Hayashi T et al. Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. *Cancers* (Basel). 2019 Aug 12;11(8). pii: E1153
63. Jang H et al. Association between the Dietary Inflammatory Index and Risk for Cancer Recurrence and Mortality among Patients with Breast Cancer. *Nutrients*, 2018, 10 (8): 1095
64. Kaluza J et al. Influence of anti-inflammatory diet and smoking on mortality and survival in men and women : two prospective cohort studies. *J Intern Med*, 12 septembre 2018
65. Lowndess SA et al. The role of copper in tumour angiogenesis. *J Mammary Gland Biol Neoplasia*, 2005, 10, 4 : 299–310
66. Qian BZ. Inflammation fires up cancer metastasis. *Semin Cancer Biol*, 2017 Aug 31, pii: S1044-579X(17) 30210-9
67. Phillips CM et al. Dietary Inflammatory Index and Non-Communicable Disease Risk: A Narrative Review. *Nutrients*, 2019 Aug 12;11(8). pii: E1873
68. Shinko D et al. Cancer-related systemic inflammation: The challenges and therapeutic opportunities for personalized medicine. *Clin Pharmacol Ther*, 2017 Oct; 102(4) :599-610
69. Shivappa N et al. Designing and developing a literature-derived, population-based dietary inflammatory index. *Public Health Nutr*, 2014, 17 (8) : 1689-96
70. Singh N et al. Inflammation and cancer. *Ann Afr Med*, 2019 Jul-Sep;18(3):121-126
71. Torti SV et al. Iron and cancer: more ore to be mined. *Nat Rev Cancer*, 2013, 13 (5) : 342–355.
72. Triantafyllidis JK et al. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. *Anticancer Res*, 2009, 29 (7) : 2727-37
73. Zamora-Ros R et al. Dietary inflammatory index and inflammatory gene interactions in relation to colorectal cancer risk in the Bellvitge colorectal cancer case-control study. *Genes Nutr*, 2015 ; 10(1) : 44
74. Zitvogel L et al. Nutrition, inflammation and cancer. *Nat Immunol.*, 2017 Jul 19; 18 (8):843-850
75. Zucchetto Antonella et al. Dietary inflammatory index and prostate cancer survival. *Int J Cancer.*, 2016, 139(11) : 2398–2404

Hormone de croissance et cancers

76. Boguszewski CL and Boguszewski MCDS. Growth Hormone's Links to Cancer. *Endocr Rev*, 2019 Apr 1;40(2):558-574
77. Chesnokova V et al. Excess growth hormone suppresses DNA damage repair in epithelial cells. *JCI Insight*, 2019 Feb 7;4(3). pii: 125762
78. Lu M et al. Targeting growth hormone function: strategies and therapeutic applications. *Signal Transduct Target Ther*, 2019 Feb 8;4:3
79. Perry JK et al. Growth hormone and cancer : an update on progress. *Curr Opin Endocrinol Diabetes Obes*, 2013, 20 (4) : 307-13

Surpoids, Obésité et cancers

80. Agurs-Collins T et al. The Many Faces of Obesity and Its Influence on Breast Cancer Risk. *Front Oncol*, 2019 Sep 4;9:765
81. Frasca D et al. Adipose Tissue: A Tertiary Lymphoid Organ: Does It Change with Age? *Gerontology*, 2019 Aug 14:1-8
82. Gaillard RC. Le tissu adipeux : un véritable organe endocrine. *Rev Med Suisse*, 2003; volume -1.22822
83. Goralski KB et al. More Than an Adipokine: The Complex Roles of Chemerin Signaling in Cancer. *Int J Mol Sci*, 2019 Sep 26;20(19). pii: E4778
84. Hu H et al. Visceral adipose tissue and the risk of colorectal adenomas : a meta-analysis of observational studies. *Eur J Cancer Prev*, 2014 Dec 9
85. Jacobs EJ et al. The Association of Body Mass Index with Pancreatic Cancer: Variation by Age at Body Mass Index Assessment. *Am J Epidemio*, 2019 Oct 11. pii: kwz230
86. Laurent V et al. Tissu adipeux et cancer, Une association à haut risque. *Med Sci (Paris)*. 2014 April; 30(4): 398–404
87. Liu R and Nikolajczyk BS. Tissue Immune Cells Fuel Obesity-Associated Inflammation in Adipose Tissue and Beyond. *Front Immunol*, 2019 Jul 17;10:1587
88. Naik A et al. The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer. *Front Immunol*, 2019 Aug 14;10:1940
89. Picon-Ruiz M et al. Obesity and adverse breast cancer risk and outcome : Mechanistic insights and strategies for intervention. *CA Cancer J Clin*, 2017 Sept67(5):378-397
90. Sánchez-Jiménez F et al. Obesity and Breast Cancer: Role of Leptin. *Front Oncol*, 2019 Jul 18;9:596
91. Wagner M et al. Adipose tissue macrophages : the inflammatory link between obesity and cancer ? *Expert Opin Ther Targets*, 2014 Dec 4 : 1-12
92. Yehuda-Shnaim E et al. Secreted human adipose leptin decreases mitochondrial respiration in HCT116 colon cancer cells. *PLoS One*, 2013 ; 8 (9)
93. Wu X. Cancer-associated adipocytes: key players in breast cancer progression. *J Hematol Oncol*, 2019 Sep 10;12(1):95
94. Zhou B et al. Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. *Pancreatology*, 2019 Aug 16. pii: S1424-3903(19)30689-1

Viande, produits laitiers et cancers

95. Adebamowo CA et al. High school dietary dairy intake and teenage acne. *J Am Acad Dermatol*, 2005 ; 52 (2) : 207-14
96. Aune D et al. Dairy products, calcium, and prostate cancer risk : a systematic review and meta-analysis of cohort studies. *Am J Clin Nutr*, 2015 Jan ; 101 (1) : 87-117 19
97. Di Maso M et al. Food consumption, meat cooking methods and diet diversity and the risk of bladder cancer. *Cancer Epidemiol*, 2019 Sep 26;63:101595
98. Ganmaa D et al. The experience of Japan as a clue to the etiology of testicular and prostatic cancers. *Med Hypotheses*, 2003, 60 (5) : 724-30
99. Goldie YL et al. Targeting cancer by binding iron : dissecting cellular signaling pathways. *Oncotarget*, 2015, 6 (22) : 18748–18779
100. Grant WB et al. An ecological study of cancer mortality rates including indices for dietary iron and zinc. *Anticancer Res*, 2008 ; 28 (3B) : 1955-63
101. Hedlund M et al. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. *Proc Natl Acad Sci U S A*, 2008, 105 (48) : 18936-41
102. Hogervorst JG et al. A prospective study of dietary acrylamide intake and the risk of endometrial, ovarian, and breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2007; 16 (11) : 2304-13
103. Hyun-Wook Lee et al. Acrolein- and 4-Aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. *Oncotarget*, 2001, 4 ; 5 (11) : 3526–3540
104. Kolaheh F et al. Meat, fish, and ovarian cancer risk : Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr*, 2010; 91 (6) : 1752-63
105. Koutros S et al. Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer. *Cancer Res*, 2009, 1 ; 69 (5) : 1877-84
106. Kroenke CH et al. High- and low-fat dairy intake, recurrence, and mortality after breast cancer diagnosis. *J Natl Cancer Inst*, 2013, 105 (9) : 616-23
107. Kuriki K et al. The increasing incidence of colorectal cancer and the preventive strategy in Japan. *Asian Pacific J Cancer Prev*, 2000, 7, 495-501
108. McCullough ML et al. Association between red and processed meat intake and mortality among colorectal cancer survivors. *J Clin Oncol*, 2013, 31 (22) : 2773–2782
109. Mursu J et al. Dietary supplements and mortality rate in older women : the Iowa Women's Health Study. *Arch Intern Med*, 2011 ; 171 (18) : 1625-33
110. Parada H, Jr. et al. Grilled, barbecued, and smoked meat intake and survival following breast cancer. *J Natl Cancer Inst*, 2017, 109 (6) : djw299
111. Pelucchi C et al. Dietary acrylamide and cancer risk : An updated meta-analysis. *Int J Cancer*. 2015 Jun 15;136(12):2912-22
112. Pelucchi C et al. Exposure to acrylamide and human cancer - a review and meta-analysis of epidemiologic studies. *Ann Oncol*, 2011; 22 (7) : 1487-99
113. Qin LQ et al. Milk consumption and circulating insulin-like growth factor-I level : a systematic literature review. *Int J Food Sci Nutr*, 2009, 60 Suppl 7 : 330-40
114. Stott-Miller M et al. Consumption of deep-fried foods and risk of prostate cancer. *Prostate*, 2013; 73 (9): 960–969.
115. Torti SV et al. Iron and cancer: more ore to be mined. *Nat Rev Cancer*, 2013, 13 (5) : 342–355.
116. Vijayvergia N et al, Lifestyle Factors in Cancer Survivorship : where We Are and Where We Are Headed, *J Pers Med*, 2015, 5 (3) : 243–263
117. Zheng W et al. Well-done meat intake, heterocyclic amine exposure, and cancer risk. *Nutr Cancer*, 2009, 61 (4) : 437–446

Sucres et cancers

118. <http://www.medicalnewstoday.com/articles/307428.php>
119. <http://www.medicalnewstoday.com/articles/308679.php>
120. Cancer : une question de vie et de mort cellulaire : <http://www.centreducancer.be/fr/show/index/section/9/page/155>
121. Levi F et al. Macronutrients and colorectal cancer: a Swiss case-control study. *Ann Oncol*. 2002 Mar; 13(3): 369–373.

Sel et cancers

122. <https://www.cancer.be/les-cancers/facteurs-de-risque/pas-trop-de-sel> Dernière mise à jour le 23/08/2017
123. https://www.who.int/elena/titles/sodium_cvd_adults/fr/
124. World Cancer Research Fund / American Institute for Cancer Research; Food, Nutrition, Physical Activity and the Prevention of Cancer, a Global Perspective, Washington D.C. AICR, 2007.
125. Baud G et al. Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent Glucose Intestinal Uptake. *Cell Metabolism*, March 08, 2016, Vol 23, issue 3, p547-553
126. D'Elia L et al. Dietary salt intake and risk of gastric cancer. *Cancer Treat Res*, 2014;159:83-95
127. Ernest M et al. Biology of Human Sodium Glucose Transporters. *Physiol Rev*, 2011, 91: 733–794
128. Ma Y et al. High salt intake: independent risk factor for obesity? *Hypertension*, 2015 Oct;66(4):843-9
129. Shin JY et al. Relationship between salt preference and gastric cancer screening: An analysis of a nationwide survey in Korea. *Cancer Res Treat*, 2016 Jul;48(3):1037-44.
130. Zhou L et al. INTERMAP Research Group. Salt intake and prevalence of overweight/obesity in Japan, China, the United Kingdom, and the United States: the INTERMAP Study. *Am J Clin Nutr*, 2019 May 21.

Acides gras saturés (AGS), Acides gras Trans et cancers

131. Bassett JK et al. Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk. *Int J Cancer*, 2013 ; 1 33 (8) : 1882-91
132. Bidoli E et al. Macronutrients, fatty acids, cholesterol and prostate cancer risk. *Ann Oncol*, 2005 Jan; 16(1): 152–157
133. Chajès V et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC Study. *Am J Epidemiol*. 2008, 1;167(11):1312-20
134. Jackson MD et al. Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. *Cancer Causes Control*, 2012, 23 (1) : 23-33
135. O'Doherty MG et al. Dietary fat and meat intakes and risk of reflux esophagitis, Barrett's esophagus and esophageal adenocarcinoma. *Int J Cancer*, 2011,129 (6) : 1493-502
136. Pelsler C et al. Dietary Fat, Fatty Acids and Risk of Prostate Cancer in the NIH-AARP Diet and Health Study. *Cancer Epidemiol Biomarkers Prev*, 2013, 22 (4) : 697–707
137. Schwab U et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. *Food Nutr Res*, 2014; 58: 10
138. Thiébaud AC et al. Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. *J Natl Cancer Inst*, 2009; 101 (14) : 1001-11

Acides gras polyinsaturés (AGPI) Oméga-6 et cancers

139. Adam O et al. Influence of Dietary Linoleic Acid Intake with Different Fat Intakes on Arachidonic Acid Concentrations in Plasma and Platelet Lipids and Eicosanoid Biosynthesis in Female Volunteers. *Ann Nutr Metab*. 2003;47(1):31-6
140. Amézaga J et al. Altered Red Blood Cell Membrane Fatty Acid Profile in Cancer Patients. *Nutrients*. 2018 Dec 1;10(12). pii: E1853
141. Burns JL et al. Differentiating the biological effects of linoleic acid from arachidonic acid in health and disease. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 2018;135:1–4
142. Burns-Whitmore B et al. Alpha-Linolenic and Linoleic Fatty Acids in the Vegan Diet: Do They Require Dietary Reference Intake/Adequate Intake Special Consideration? *Nutrients*. 2019;11,2365
143. de Kok TM et al. Analysis of oxidative DNA damage after human dietary supplementation with linoleic acid. *Food Chem Toxicol*. 2003 Mar;41(3):351-8
144. Diaz-Aragon R et al. Role of phospholipase D in migration and invasion induced by linoleic acid in breast cancer cells. *Mol Cell Biochem*. 2019 Jul;457(1-2):119-132
145. Fritsche KL. Too much linoleic acid promotes inflammation-doesn't it? *Prostaglandins Leukot Essent Fatty Acids*. 2008 Sep-Nov;79(3-5):173-5
146. Guichardant M et al. Biological relevance of double lipoxygenase products of polyunsaturated fatty acids, especially within blood vessels and brain. *Biochimie*. April 2019;159:55-58
147. Hill EM et al. Dietary polyunsaturated fatty acids modulate adipose secretome and is associated with changes in mammary epithelial stem cell self-renewal. *J Nutr Biochem*. 2019 Sep;71:45-53
148. Huerta-Yépez S et al. Role of diets rich in omega-3 and omega-6 in the development of cancer. *Bol Med Hosp Infant Mex*. 2016 Nov - Dec;73(6):446-456
149. Ines JK and Calder PC. Omega-6 fatty acids and inflammation. *Prostaglandins, Leukotrienes and Essential Fatty Acids*. 2018; 132:41–48
150. Khadge S et al. Immune regulation and anti-cancer activity by lipid inflammatory mediators. *Int Immunopharmacol*. 2018 Dec;65:580-592
151. Lira LG et al. Plasma and erythrocyte omega-3 and omega-6 fatty acids are associated with multiple inflammatory and oxidative stress biomarkers in breast cancer. *Nutrition*. 2019 Feb;58:194-200
152. Loew A et al. A Role for Lipid Mediators in Acute Myeloid Leukemia. *Int J Mol Sci*. 2019 May 16;20(10). pii: E2425
153. Marangoni F et al. Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. *Atherosclerosis*. 2020;292:90–98
154. Nagata M et al. The ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cancer death in a Japanese community: The Hisayama Study. *Journal of Epidemiology*. 2017;27:578e583
155. Naughton SS et al. Linoleic acid and the pathogenesis of obesity. *Prostaglandins & other Lipid Mediators*. 2016;125:90–99
156. Nindrea RD et al. Association of Dietary Intake Ratio of n-3/n-6 Polyunsaturated Fatty Acids with Breast Cancer Risk in Western and Asian Countries: A Meta-Analysis. *Asian Pac J Cancer Prev*. 2019 May 25;20(5):1321-1327
157. Peppone LJ et al. Multicenter Randomized Controlled Trial of Omega-3 Fatty Acids Versus Omega-6 Fatty Acids for the Control of Cancer-Related Fatigue Among Breast Cancer Survivors. *JNCI Cancer Spectr*. 2019 Jun;3(2):pkz005
158. Rett BS, Whelan J. Increasing dietary linoleic acid does not increase tissue arachidonic acid content in adults consuming Western-type diets: a systematic review. *Nutr Metab (Lond)*. 2011 Jun 10;8:36
159. Silva JR et al. Wound Healing and Omega-6 Fatty Acids: From Inflammation to Repair. *Mediators Inflamm*. 2018 Apr 12;2018:2503950
160. Yarla NS et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. *Semin Cancer Biol*. 2016 Oct;40-41:48-81

Quelles sont les pistes de solutions ? Zoom sur l'alimentation et nutriments

Végétaux et cancers

161. Aleksandrova K et al. Combined impact of healthy lifestyle factors on colorectal cancer: a large European cohort study. *BMC Med*, 2014, 12 (1) : 168
162. Allen NE et al. Macronutrient intake and risk of urothelial cell carcinoma in the European prospective investigation into cancer and nutrition. *Int J Cancer*, 2013 Feb 1; 132 (3) : 635-44
163. Béliveau R. La méthode anti-cancer, comment réduire les risques. *Flammarion*, 2014.
164. Epplein M et al. Fruit and Vegetable Consumption and Risk of Distal Gastric Cancer in the Shanghai Women's and Men's Health Studies. *Am J Epidemiol*, 15, 2010, 172(4) : 397-406
165. Hastert TA et al. Adherence to WCRF/AICR cancer prevention recommendations and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*, 2013, 22 (9) : 1498-508
166. Johansson G et al. Dietary influence on some proposed risk factors for colon cancer: fecal and urinary mutagenic activity and the activity of some intestinal bacterial enzymes. *Cancer Detect Prev*, 1997, 21 (3) : 258-66
167. Key TJ et al. Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans. *Am J Clin Nutr*, 2014 ; 100 (Supplement 1) : 378S-385S
168. Le LT et al. Beyond Meatless, the Health Effects of Vegan Diets: Findings from the Adventist Cohorts. *Nutrients*, Jun 2014 ; 6 (6) : 2131-2147
169. Reglero C, Reglero G. Precision Nutrition and Cancer Relapse Prevention: A Systematic Literature Review. *Nutrients*. 2019 Nov 16;11(11). pii: E2799
170. Servan-Schreiber D. Anticancer : Prévenir et lutter grâce à nos défenses naturelles. *Robert Laffont*, 2007
171. Siegel EM et al. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. *Gynecol Oncol*, 2010 ; 118 (3) : 289-94
172. Sreedhar A. Next-Gen Therapeutics for Skin Cancer: Nutraceuticals. *Nutr Cancer*. 2018 Jul;70(5):697-709
173. Wang X et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. *BMJ*, 2014 ; 349 : g4490

Crucifères et cancers

174. Aggarwal BB et al. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. *Cell Cycle*, 2005, 4 (9) : 1201-15
175. Ampofo E et al. Targeting the microcirculation by indole-3-carbinol and its main derivate 3,3'-diindolylmethane : effects on angiogenesis, thrombosis and inflammation. *Mini Rev Med Chem*. 2018, 18 (11) : 962-968
176. Barrera LN et al. Epigenetic and antioxidant effects of dietary isothiocyanates and selenium : potential implications for cancer chemoprevention. *Proc Nutr Soc*, 2012, 71 (2) : 237-45
177. Bradlow HL et al. 2-hydroxy-oestrone : the 'good' estrogen. *J.Endocrinol.*,1996. 150 suppl S259-65
178. Chen DZ et al. Indole-3-carbinol and diindolylmethane induce apoptosis of human cervical cancer cells and in murine HPV16-transgenic preneoplastic cervical epithelium. *J Nutr*, 2001, 131 : 3294-302.
179. Chinni SR et al. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. *Clin Cancer Res*, 2002, 8 : 1228-36.
180. Choi HS et al. Indole-3-carbinol induces apoptosis through p53 and activation of caspase-8 pathway in lung cancer A549 cells. *Food Chem Toxicol*. 2010, 48(3) : 883-90.
181. Cover CM et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. *J Biol Chem*, 1998; 273 : 3838-47.
182. Cover CM et al. Indole-3-carbinol and Tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. *Cancer Res*, 1999, 59 :1244-51.
183. Hong C et al. Bcl-2 family-mediated apoptotic effects of 3,3'-diindolylmethane (DIM) in human breast cancer cells. *Biochem Pharmacol*, 2002, 63 (6) : 1085-97.
184. Hwang C et al. Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. *Am J Transl Res.*, 2016, 8 (1) : 166-176
185. Keshandehghan A et al. Co-Treatment with Sulforaphane and Nano-Metformin Molecules Accelerates Apoptosis in HER2+ Breast Cancer Cells by Inhibiting Key Molecules. *Nutr Cancer*. 2019 Sep 2:1-14
186. Liu X et al. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. *Breast*, 2013, 22 (3) : 309-13
187. Nachshon-Kedmi M et al. Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. *Food Chem Toxicol*, 2003, 41 (6) : 745-52.
188. Navarro SL et al. Mechanisms of action of isothiocyanates in cancer chemoprevention : an update. *Food Funct*, 2011, 2 (10) : 579-87
189. Singh-Gupta V et al. B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer. *Cancer Lett.*, 2012, 318 (1) : 86-92
190. Tang L et al. Cruciferous vegetable intake is inversely associated with lung cancer risk among smokers : a case-control study. *BMC Cancer*, 2010, 10: 162
191. Tang L et al. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. *Cancer Epidemiol Biomarkers Prev*, 2008, 17 (4) : 938-44

192. Taylor-Harding B et al. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. *Br J Cancer*, 2012, 106 (2) : 333–343
193. Wu QJ et al. Cruciferous vegetable consumption and gastric cancer risk : a meta-analysis of epidemiological studies. *Cancer Sci*, 2013, 104 (8) : 1067-73
194. Wu QJ et al. Cruciferous vegetables intake and the risk of colorectal cancer : a meta-analysis of observational studies. *Ann Oncol*, 2013, 24 (4) : 1079–1087

Alliacées et cancers

195. Asemani Y et al. Allium vegetables for possible future of cancer treatment. *Phytother Res*, 2019 Aug 29
196. Djuric Z et al. Association of Dietary Quercetin with Reduced Risk of Proximal Colon Cancer. *Nutr Cancer*, 2012; 64(3): 351–360.
197. Galeone C et al. Onion and garlic use and human cancer. *Am J Clin Nutr*, 2006, 84 (5) : 1027-32
198. Gao CM et al. Protective effect of allium vegetables against both esophageal and stomach cancer : a simultaneous case-referent study of a high-epidemic area in Jiangsu Province, China. *Jpn J Cancer Res*, 1999; 90 (6) : 614-21
199. Huang J et al. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β -catenin signaling pathway. *Mol Nutr Food Res.*, 2015, 59 (6) :1063-75
200. Ishikawa H et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. *J Nutr*, 2006, 136 (3 Suppl) : 816S-820S
201. Lai KC et al. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo. *Phytomedicine*, 2012,19 (7) : 625-30
202. Miroddi M et al. Potential beneficial effects of garlic in oncohematology. *Mini Rev Med Chem*, 2011, 11 (6) : 461-72
203. Morales-González JA et al. Garlic (*Allium sativum* L.): A Brief Review of Its Antigenotoxic Effects. *Foods*, 2019 Aug 13;8(8). pii: E343
204. Nicastro HL et al. Garlic and onions : their cancer prevention properties. *Cancer Prev Res (Phila)*, 2015 Jan 13
205. Peyman M et al. Therapeutic Uses and Pharmacological Properties of Garlic, Shallot, and Their Biologically Active Compounds. *Iran J Basic Med Sci*, 2013, 16 (10) : 1031–1048
206. Setiawan VW et al. Allium Vegetables and Stomach Cancer Risk in China. *Asian Pac J Cancer Prev*, 2005 ; 6 (3) : 387–395
207. Su B et al. Diallyl disulfide inhibits TGF β 1 induced upregulation of Rac1 and β catenin in epithelial mesenchymal transition and tumor growth of gastric cancer. *Oncol Rep.*, 2018, 39 (6) : 2797-2806
208. Tsubura A et al. Anticancer effects of garlic and garlic-derived compounds for breast cancer control. *Anticancer Agents Med Chem*, 2011, 11(3) : 249-53
209. Wang X et al. Aged black garlic extract induces inhibition of gastric cancer cell growth in vitro and in vivo. *Mol Med Rep*, 2012, 5 (1) : 66-72

Algues, champignons et cancers

210. Alonso EN et al. Genes Related to Suppression of Malignant Phenotype Induced by Maitake D-Fraction in Breast Cancer Cells. *J Med Food*, 2013, 16 (7) : 602–617
211. Ayeka PA et al. Potential of Mushroom Compounds as Immunomodulators in Cancer Immunotherapy : a review. *Evid Based Complement, Alternat Med.*, 2018, 2018 : 7271509
212. Cheng S et al. Ganoderma lucidum for cancer treatment : we are close but still not there. *Integr Cancer Ther*, 2015, 14 (3) : 249-57
213. Deng G et al. A phase I/II trial of a polysaccharide extract from *Grifola frondosa* (Maitake mushroom) in breast cancer patients : immunological effects. *J Cancer Res Clin Oncol*, 2009, 135 (9) : 1215-1221
214. Elbatrawy EN et al. Medicinal Mushroom Extracts Possess Differential Antioxidant Activity and Cytotoxicity to Cancer Cells. *Int J Med Mushrooms*, 2015,17 (5) : 471-9
215. Fitton JH et al. Therapies from Fucoïdan : an update. *Mar Drugs*, 2015, 13 (9) : 5920–5946
216. Funahash H et al. Seaweed prevents breast cancer ? *Jpn. J. Cancer Res*, 2001, 92 (5) : 483 - 487.
217. Jin X et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. *Cochrane Database Syst Rev*, 2012, (6) : CD007731
218. Kladar NV et al. Ganoderma : insights into anticancer effects. *Eur J Cancer Prev*, 2015 Aug 27
219. Kodama N et al. Can maitake MD-fraction aid cancer patients ? *Altern Med Rev*, 2002, 7 (3) : 236-9
220. Kwak JY et al. Fucoïdan as a Marine Anticancer Agent in Preclinical Development. *Mar Drugs*, 2014, 12 (2) : 851–870
221. Lindequist U et al. The Pharmacological Potential of Mushrooms. *Evid Based Complement, Alternat Med*, 2005, 2 (3) : 285–299
222. Liu J et al. Combined Yeast-derived β -Glucan with Anti-tumor Monoclonal Antibody for Cancer Immunotherapy. *Exp Mol Pathol*, 2009, 86 (3) : 208–214
223. Ma HT et al. Anti-diabetic effects of Ganoderma lucidum. *Phytochemistry*, 2015 Jun, 114 : 109-13
224. Martin LJ et al. Fucoxanthin and Its Metabolite Fucoxanthinol in Cancer Prevention and Treatment. *Marine Drugs*, 2015, 13 (8) : 4784–98
225. Moghadamtousi SZ et al. Anticancer and Antitumor Potential of Fucoïdan and Fucoxanthin, Two Main Metabolites Isolated from Brown Algae. *Scientific World Journal*, 2014, 2014 : 768323
226. Okam K et al. Adjuvant immunotherapy : two randomized controlled studies of patients with cervical cancer. *Biomedicine Pharmacotherapy*, 1989, 43, 3, 177-181
227. Rokkaku T et al. Anticancer effects of marine carotenoids, fucoxanthin and its deacetylated product, fucoxanthinol, on osteosarcoma. *Int J Oncol*, 2013, 43 (4) : 1176-86
228. Rossi P et al. β -glucans from *Grifola frondosa* and *Ganoderma lucidum* in breast cancer : an example of complementary and integrative medicine. *Oncotarget*, 2018, 9 (37) : 24837–24856

229. Satomi Y et al. Antitumor and Cancer-preventative Function of Fucoxanthin : a Marine Carotenoid. *Anticancer Research*, 2017, 37 (4) : 1557–1562
230. Suzuki N et al. Efficacy of oral administration of Lentinula edodes mycelia extract for breast cancer patients undergoing postoperative hormone therapy. *Asian Pac J Cancer Prev*, 2013, 14 (6) : 3469-72
231. Taguchi T et al. Life-span prolongation effect of lentinan on patients with advanced or recurrent colorectal cancer. *Int J Immunopharmacol*, 1982, 4 : 271
232. Tanigawa K et al. Improvement of QOL and Immunological Function With Lentinula Edodes Mycelia in Patients Undergoing Cancer Immunotherapy : an Open Pilot Study. *Altern Ther Health Med*, 2016, 22 (4) : 36-42
233. Teas J et al. Dietary seaweed modifies estrogen and phytoestrogen metabolism in healthy postmenopausal women. *J Nutr*, 2009, 139 (5) : 939 - 944
234. Valverde ME et al. Edible Mushrooms : Improving Human Health and Promoting Quality Life. *Int J Microbiol*, 2015, 2015 : 376387
235. Xu T et al. The cancer preventive effects of edible mushrooms. *Anticancer Agents Med Chem*, 2012, 12 (10) : 1255-63
236. Yamaguchi Y et al. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy : a pilot study. *Am J Chin Med*, 2011, 39 (3) : 451-9
237. Yang YJ. A case-control study on seaweed consumption and the risk of breast cancer. *Br J Nutr*, 2010, 103 (9) : 1345-1353
238. Zhang Y et al. Lentinan as an immunotherapeutic for treating lung cancer : a review of 12 years clinical studies in China. *J Cancer Res Clin Oncol*, 2018 Jul 24
239. Hang S et al. Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study. *Int J Cancer*, 2019 Sep 4

Polyphénols et cancers

240. Arora I et al. Combinatorial Epigenetics Impact of Polyphenols and Phytochemicals in Cancer Prevention and Therapy. *Int J Mol Sci*, 2019 Sep 14;20(18). pii: E4567

Thé, catéchines et cancers

241. Ahn WS et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. *Eur J Cancer Prev*, 2003, 12 (5) : 383-90.
242. Beltz LA et al. Mechanisms of cancer prevention by green and black tea polyphenols. *Anticancer Agents Med Chem.*, 2006, 6 (5) : 389-406
243. Bettuzzi S et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia : a preliminary report from a one-year proof-of-principle study. *Cancer Res*, 2006, 66 (2) : 1234-40
244. Brausi M et al. Chemoprevention of human prostate cancer by green tea catechins : two years later. A follow-up update. *Eur Urol*, 2008, 54 (2) : 472-3
245. Dostal AM et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer : results of the Minnesota Green Tea Trial. *Food Chem Toxicol*, 2015 Sept, 83 : 26-35
246. Fujiki H et al. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins and anticancer compounds. *J Cancer Res Clin Oncol.*, 2015 Sep ; 14 (9) :1511-22
247. Hayakawa S et al. Anti-cancer effects of green tea by either anti- or pro-oxidative mechanisms. *Asian Pac J Cancer Prev*, 2016 ;17(4) :1649-54
248. Henning S et al. Chemopreventive Effects of Tea in Prostate Cancer: Green Tea vs. Black Tea. *Mol Nutr Food Res*, 2011, 55 (6), 905–920
249. Islam RH et al. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. *Egyptian Journal of Basic and Applied Sciences*, 2018, 5, 1, 1-23
250. Jianhua C et al. Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of anti-tumor activity, toxicology and pharmacokinetics. *Nutrients*, 2016 Dec, 8 (12) : 762
251. Khan N et al. Multitargeted therapy of cancer by green tea polyphenols. *Cancer Lett*, 2008 Oct 8, 269 (2) : 269-280
252. Khan N et al. Cancer and metastasis : prevention and treatment by green tea, *Cancer Metastasis Rev*, 2010, 29, 435-445
253. Li Y et al. Synergistic epigenetic reactivation of estrogen receptor- α (ER α) by combined green tea polyphenol and histone deacetylase inhibitor in ER α -negative breast cancer cells. *Mol Cancer*, 2010, 9, 274
254. McLarty J et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. *Cancer Prev Res (Phila)*, 2009, 2 (7) : 673-82
255. Meeran SM et al. Bioactive Dietary Supplements Reactivate ER Expression in ER-Negative Breast Cancer Cells by Active Chromatin Modifications. *PLoS One*, 2012, 7 (5) : e37748
256. Nakachi K et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. *Jpn J Cancer Res*, 1998, 89 (3) : 254-61
257. Rashidi B et al. Green tea and its anti-angiogenesis effects. *Biomed Pharmacother*, 2017 May ; 89 ; 949-956
258. Rathore K et al. Green tea catechin extract in intervention of chronic breast cell carcinogenesis induced by environmental carcinogens. *Mol Carcinog*, 2012, 51 (3) : 280-9
259. Sartippour MR et al. The combination of green tea and tamoxifen is effective against breast cancer. *Carcinogenesis*, 2006 , 27 (12) : 2424-33

260. Singh BN et al. Green tea catechin, epigallocatechin-3-gallate (EGCG) : mechanisms, perspectives and clinical applications. *Biochem Pharmacol*, 2011 ; 82 (12) : 1807-21
261. Sinha S et al. Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ER α -dependent in ER α -negative human breast cancer cells. *Mol Cell Endocrinol*, 2015 May, 406, 102-14
262. Saganuma M et al. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. *Cancer Sci*, 2011, 102 (2) : 317-23
263. Thomas R et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer – the UK NCRN Pomi-T study. *Prostate Cancer Prostatic Dis*, 2014 Jun, 17 (2) : 180–186
264. Zou C et al. Green tea compound in chemoprevention of cervical cancer. *Int J Gynecol Cancer*, 2010, 20 (4) : 617-24.

Curcuma, Curcumine et cancers

265. <https://www.cancer.be/complementsalimentaires/curcuma> consulté octobre 2019
266. <http://cam-cancer.org/en/curcumin> consulté octobre 2019
267. Adiwidjaja J et al. Curcumin as a clinically-promising anti-cancer agent : pharmacokinetics and drug interactions. *Expert Opin Drug Metab Toxicol*, 2017 Sep ; 13(9) :953-972
268. Agrawal DK et al. Curcumin and its analogues : potential anticancer agents. *Med Res Rev*, 2010, 30 (5) : 818-60
269. Alemi A et al. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. *J Nanobiotechnology*, 2018, 16 (1) : 28
270. Allegra A et al. Anticancer activity of curcumin and its analogues : Preclinical and clinical studies. *Cancer Invest*, 2017 Jan 2 ; 35(1) :1-22
271. Amin AR et al. Evasion of anti-growth signaling : a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. *Semin Cancer Biol*, 2015, pii : S1044-579X (15) 00013-9
272. Bandyopadhyay D. Farmer to pharmacist : curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. *Front Chem*, 2014, 2 : 113
273. Bayet-Robert M et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. *Cancer Biol Ther*, 2010, 9 (1) : 8-14
274. Bigelsen S et al. Evidence-based complementary treatment of pancreatic cancer : a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin. *Cancer Manag Res*, 2018, 10 : 2003–2018
275. Bordoloi D et al. Multi-Targeted agents in cancer cell chemosensitization : what we learnt from curcumin thus far. *Recent Pat Anticancer Drug Discov*, 2015 Oct 19
276. Carroll RE et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. *Cancer Prev Res (Phila)*, 2011; 4 (3) : 354-64
277. Cruz-Correa M et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. *Clin Gastroenterol Hepatol*, 2006, 4 (8) : 1035-8
278. Danilenko M et al. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. *Exp Cell Res*, 2004, 298 (2) : 339-58
279. Deng YI et al. Molecular mechanisms of anti-metastatic activity of curcumin. *Anticancer Res*, 2016 Nov ; 36(11) :5639-5647
280. Dhillon N et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*, 2008, 14 (14) : 4491-9
281. Erices JI et al. Current natural therapies in the treatment against glioblastoma. *Phytother Res*, 2018 Aug 15
282. Gupta SC et al, Therapeutic roles of curcumin : lessons learned from clinical trials. *AAPS J*, 2013 Jan ; 15(1) : 195-218
283. Ide H et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*, 2010 ; 70 (10) : 1127-33
284. Jiang M et al. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. *Molecules*, 2013, 18 (1) : 701-20
285. Kanai M et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. *Cancer Chemother Pharmacol*, 2011, 68 (1) : 157-64
286. Kumar P et al. Curcumin as an adjuvant to breast cancer treatment. *Anticancer Agents Med Chem*, 2015,15 (5) : 647-56
287. Kumar B et al. A Novel Curcumin Analog (H-4073) Enhances the Therapeutic Efficacy of Cisplatin Treatment in Head and Neck Cancer. *PLoS One*, 2014; 9(3): e93208.
288. Kunnumakkara AB et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. *Int J Cancer*, 2009 Nov 1;125(9):2187-97
289. Kunnumakkara AB et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. *Cancer Res*, 2007 Apr 15;67(8):3853-61
290. Murray-Stewart T et al. Curcumin mediates polyamine metabolism and sensitizes gastrointestinal cancer cells to antitumor polyamine-targeted therapies. *PLoS One*, 2018, 13 (8) : e0202677
291. Palange AL et al. Modulating the vascular behavior of metastatic breast cancer cells by curcumin treatment. *Front Oncol*, 2012, 2, 161
292. Panahi Y. et al. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother Res*, 2014 Oct;28(10):1461-7
293. Rajah TT et al. Genistein in the presence of 17beta-estradiol inhibits proliferation of ErbA breast cancer cells. *Pharmacology*, 2009 Jun 26 ;84(2) :68-73

294. Rezaee R et al. Curcumin : A potentially powerful tool to reverse cis-platin-induced toxicity. *Pharmacol Res*, 2017 Mar, 117 :218-227
295. Scarano W et al. Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects : a double act for the treatment of multidrug-resistant cancer. *Biomater Sc*, 2015, 3 (1) : 163-74
296. Schaffer M et al. An update on Curcuma as a functional food in the control of cancer and inflammation. *Curr Opin Clin Nutr Metab Care*, 2015 Nov ; 18(6) :605-11
297. Shakeri A et al. Curcumin : a naturally occurring autophagy modulator. *J Cell Physiol*, 2018 Sep 21
298. Tuorkey MJ et al. Curcumin a potent cancer preventive agent : Mechanisms of cancer cell killing. *Interv Med Appl Sci*, 2014 Dec ; 6 (4) : 139-46
299. Terlikowska K et al. Curcumin in chemoprevention of breast cancer. *Postepy Hig Med Dosw*, 2014; 68: 571–578.
300. Wilken R et al. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. *Mol Cancer*, 2011, 10 : 12
301. Yallapu MM et al. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. *J Ovarian Res*, 2010, 3 : 11
302. Zhang P et al. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice. *J Exp Clin Cancer Res*, 2017, 36 (1) : 190

Polyphénols de grenade et cancers

303. Adhami VM et al. Cancer chemoprevention by pomegranate : laboratory and clinical evidence. *Nutr Cancer*, 2009, 61 (6) : 811-5
304. Jurenka JS. Therapeutic applications of pomegranate (*Punica granatum* L.) : a review. *Altern Med Rev*, 2008, 13 :128-44
305. Kim ND et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (*Punica granatum*) for human breast cancer. *Breast Cancer Research and Treatment*, 2002, 71 : 203–217
306. Lansky EP et al. *Punica granatum* (pomegranate) and its potential for prevention and treatment of inflammation and cancer. *J Ethnopharmacol*, 2007, 109, 2 ; 177–206
307. Malik A et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. *Proceedings of the National Academy of Sciences, USA*, 2005; 102 : 14813–14818
308. Panth N et al. Anticancer Activity of *Punica granatum* (Pomegranate) : a Review. *Phytother Res*. 2017, 31 (4) : 568-578
309. Pantuck AJ et al. Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer. *Clin Cancer Res*. 2006, 12, 13 : 4018–4026
310. Sharma P et al. Pomegranate for Prevention and Treatment of Cancer : an update. *Molecules*, 2017, 22 (1) : E177.
311. Turrini E et al. Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. *Oxid Med Cell Longev*, 2015, 2015 : 938475
312. Wang L et al. Pomegranate and its components as alternative treatment for prostate cancer. *Int J Mol Sci*, 2014, 15 (9): 14949-66
313. Wang N et al. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer. *Breast Cancer Res Treat*, 2012, 134 (3) : 943–955

Resvératrol et cancers

314. Brizuela et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. *FASEB J*, 3 juin 2010
315. Chakraborty S et al. Structural insights into Resveratrol's antagonist and partial agonist actions on estrogen receptor alpha. *BMC Struct Biol*, 2013, 13 : 27
316. da Costa DCF et al. Resveratrol prevents p53 aggregation in vitro and in breast cancer cells. *Oncotarget*. 2018, 9 (49) : 29112–29122.
317. Greving JP et al. Alcoholic beverages and risk of renal cell cancer. *Br J Cancer*, 2007, 97 (3) : 429-33
318. Grønbaek M et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. *Ann Intern Med*, 2000; 133 (6) : 411-9
319. Kim CW et al. Anti-metastatic potential of resveratrol and its metabolites by the inhibition of epithelial-mesenchymal transition, migration, and invasion of malignant cancer cells. *Phytomedicine*. 2016, 5, 23 (14) :1787-1796
320. Kundu JK et al. Cancer chemopreventive and therapeutic potential of resveratrol : mechanistic perspectives. *Cancer Lett*. 2008, 269 (2) : 243-61
321. Pelucchi C et al. Alcohol consumption and renal cell cancer risk in two Italian case-control studies. *Ann Oncol*, 2008, 19 (5) : 1003-8
322. Renaud SC et al. Wine, beer, and mortality in middle-aged men from eastern France. *Arch Intern Med*, 1999 ; 159 (16) : 1865-70
323. Yang Y et al. Differential sensitivities of bladder cancer cell lines to resveratrol are unrelated to its metabolic profile. *Oncotarget*, 2017, 8 (25) : 40289–40304.

Caroténoïdes et cancers

324. Etminan M et al. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. *Cancer Epidemiol Biomarkers Prev*, 2004 ; 13 (3): 340-5

325. Gann PH et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. *Cancer Res*, 1999; 59(6):1225–1230
326. Giovannucci E et al. Intake of carotenoids and retinol in relation to risk of prostate cancer. *J Natl Cancer Inst*, 1995; 87(23):1767–1776
327. Han H et al. Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells. *Nutrients*, 2019 Sep 5;11(9)
328. Haseen F et al. Is there a benefit from lycopene supplementation in men with prostate cancer ? A systematic review. *Prostate Cancer Prostatic Dis.*, 2009, 12 (4) : 325-32
329. Hughes DA. Effects of carotenoids on human immune function. *Proceedings of the Nutrition Society*, 1999, 58, 713–718
330. Kirsh VA et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*, 2006; 15(1):92–98
331. Kucuk O et al. Effects of lycopene supplementation in patients with localized prostate cancer. *Exp Biol Med (Maywood)*, 2002, 227 (10) : 881-5
332. Marti R et al. Tomato as a source of carotenoids and polyphenols targeted to cancer prevention. *Cancers (Basel)*, 2016 Jun 20, 8 (6)
333. Paur I et al. Tomato-based randomized controlled trial in prostate cancer patients. Effect on PSA. *Clin Nutr*, 2016, S0261-5614 (16) 30147-9
334. Schwarz S et al. Lycopene inhibits disease progression in patients with benign prostate hyperplasia. *J Nutr*, 2008 ; 138 (1) : 49-53
335. Soares NCP et al. Lycopene Extracts from Different Tomato-Based Food Products Induce Apoptosis in Cultured Human Primary Prostate Cancer Cells and Regulate TP53, Bax and Bcl-2 Transcript Expression. *Asian Pac J Cancer Prev.*, 2017, 18 (2) : 339–345.
336. van Breemen R et al. Multitargeted therapy of cancer by lycopene. *Cancer Lett*, 2008, 269 (2) : 339–351.
337. Zhang X et al. Lycopene can reduce prostate-specific antigen velocity in a phase II clinical study in Chinese population. *Chin Med J (Engl)*, 2014, 127 (11) : 2143-6
338. Zu K et al. Dietary lycopene, angiogenesis, and prostate cancer : a prospective study in the prostate-specific antigen era. *J Natl Cancer Inst*, 2014;106 (2) : djt430

Oméga 3 et cancers

339. Abdi J et al. Omega-3 fatty acids, EPA and DHA induce apoptosis and enhance drug sensitivity in multiple myeloma cells but not in normal peripheral mononuclear cells. *J Nutr Biochem*, 2014 Dec, 25 (12) : 1254-62
340. Abe K et al. Effects of ω -3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. *Anticancer Res.*, 2018, 38 (4) : 2369-2375
341. Albino AP et al. Cell cycle arrest and apoptosis of melanoma cells by docosahexaenoic acid: association with decreased pRb phosphorylation. *Cancer Res*, 2000, 60 (15) : 4139-45
342. Bagga D et al. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. *Nutr Cancer*, 2002, 42:180
343. Baker E. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. *Progress in Lipid Research*, 2016 ; 64 : 30–56
344. Berquin IM et al. Multi-targeted therapy of cancer by omega-3 fatty acids. *Cancer Lett.*, 2008 Oct 8 ; 269 (2) : 363-377
345. Bougnoux P et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid : a phase II trial. *Br J Cancer*, 2009, 101 (12) : 1978–1985
346. Brasky MT et al. Specialty Supplements and Breast Cancer Risk in the VITamins And Lifestyle (VITAL) Cohort. *Cancer Epidemiol Biomarkers Prev*, 2010, 19 (7) : 1696–1708.
347. Calder PC et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. *Ageing Res Rev*. 2017 Nov;40:95-119
348. Chajès V et al. Association between serum trans-monounsaturated fatty acids and breast cancer risk in the E3N-EPIC study. *Am J Epidemiol*, 2008 Apr 4
349. Cockbain AJ et al. Anticorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. *Gut*, 2014 Nov, 63 (11) : 1760-8
350. de Lorgeril M et al. Helping women to good health : breast cancer, omega-3/omega-6 lipids, and related lifestyle factors. *BMC Med*, 2014, 12 : 54
351. Epstein MM et al. Dietary fatty acid intake and prostate cancer survival in Örebro County, Sweden. *Am J Epidemiol*, 2012, 176 (3) : 240-5
352. Friedrichs W et al. Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. *Nutr Cancer*, 2011, 63 (5) : 771-7
353. Golkhalkhali B et al. Strain-specific probiotic (microbial cell preparation) and omega-3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients : a randomized controlled trial. *Asia Pac J Clin Oncol*, 2018, 14 (3) : 179-191
354. Goodstine SL et al. Dietary (n-3)/(n-6) fatty acid ratio: possible relationship to premenopausal but not postmenopausal breast cancer risk in U.S. women. *J Nutr*, 2003, 133:1409
355. Greupner T et al. Effects of a 12-week high- α -linolenic acid intervention on EPA and DHA concentrations in red blood cells and plasma oxylipin pattern in subjects with a low EPA and DHA status. *Food Funct.*, 2018, 9, 1587
356. Hajjaji N and Bougnoux P. Selective sensitization of tumors to chemotherapy by marine-derived lipids : a review. *Cancer Treat Rev*, 2013, 39 (5) : 473-88
357. Hardman WE. (n-3) fatty acids and cancer therapy. *J Nutr*, 2004 ; 134 (12 Suppl) : 3427S-3430S

358. Harvey KA et al. Enhanced anticancer properties of lomustine in conjunction with docosahexaenoic acid in glioblastoma cell lines. *J Neurosurg*, 2015 Mar,122 (3) : 547-56
359. Hsu HC et al. N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes - involvement of uncoupling protein UCP2. *J Biomed Sci*, 2014 Nov, 21 : 101
360. Jeongseon K et al. Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk : a case-control study. *BMC Cancer*, 2009, 9 : 216
361. Joffre C et al. N-3 Polyunsaturated Fatty Acids and the Resolution of Neuroinflammation. *Frontiers in Pharmacology*, September 2019; Volume 10 | Article 1022
362. Kolahdooz F et al. Meat, fish, and ovarian cancer risk : Results from 2 Australian case-control studies, a systematic review, and meta-analysis. *Am J Clin Nutr*, 2010, 91 (6) : 1752-63
363. Lagarde M et al. Structure-function relationships of non-cyclic dioxygenase products from polyunsaturated fatty acids: poxytrins as a class of bioactive derivatives. *Biochimie*, Dec 2014; 107(Pt A): 91–94
364. Manda K et al. Omega-3 fatty acid supplementation i cancer therapy : does eicosapentanoic acid influence the radiosensitivity of tumor cells ? *Strahlenther Onkol.*, 2011 Feb ; 187(2) :127-34
365. Maillard V et al. N-3 and N-6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case-control study in Tours, France. *Int J Cancer*, 2002, 98:78
366. Miyata H et al. Randomized study of the clinical effects of ω -3 fatty acid-containing enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. *Nutrition*, 2017, 33 : 204-210
367. Murphy RA et al. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. *Cancer*, 2011,117 (16) : 3774-80
368. Nakamura K et al. Influence of preoperative administration of omega-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. *Nutrition*, 2005, 21 (6) : 639-49
369. Pala V et al. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. *J Natl Cancer Inst*, 2001, 18;93(14):1088-95
370. Pardini RS et al. Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. *Chem Biol Interact*, 2006, 162 (2) :89-105
371. Pastore CA et al. Introduction of an omega-3 enriched oral supplementation for cancer patients close to the first chemotherapy : may it be a factor for poor compliance ? *Nutr Cancer*, 2014, 66 (8) : 1285-92
372. Patterson R et al. Marine Fatty Acid Intake Is Associated with Breast Cancer Prognosis. *J Nutr.*, 2011, 141 (2) : 201–206
373. Piazzini G et al. Eicosapentaenoic acid free fatty acid prevents and suppresses colonic neoplasia in colitis-associated colorectal cancer acting on Notch signaling and gut microbiota. *Int J Cancer*, 2014, 135 (9) : 2004-13
374. Pouchieu C et al. Prospective Associations between Plasma Saturated, Monounsaturated and Polyunsaturated Fatty Acids and Overall and Breast Cancer Risk – Modulation by Antioxidants : A Nested Case-Control Study. *PLoS One*. 2014; 9(2): e90442
375. Sawada N et al. Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma. *Gastroenterology*, 2012 ; 142 (7) : 1468-75
376. Shannon J et al. Erythrocyte fatty acids and breast cancer risk : a case-control study in Shangaï, China. *Am J Clin Nutr*. 2007 Apr ;85(4) :1090-7
377. Siddiqui RA et al. Docosahexaenoic acid : a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. *Biofactors*, 2011 Nov-Dec ; 37(6) :399-412
378. Simonsen et al. Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. *Am J Epidemiology*, 1998, 147:342
379. Szymanski KM et al. Fish consumption and prostate cancer risk : a review and meta-analysis. *Am J Clin Nutr*, 2010, 92 (5) : 1223-33
380. Takezaki T et al. Diet and lung cancer risk from a 14-year population-based prospective study in Japan : with special reference to fish consumption. *Nutr Cancer*, 2003, 45 (2) : 160-7
381. Thiébaud AC et al. Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer. *Int J Cancer*, 2009, 124 (4) : 924-31
382. Vasudevan A et al. Omega-3 fatty acid is a potential preventive agent for recurrent colon cancer. *Cancer Prev Res (Phila)*, 2014 Sept 5.
383. Villani AM et al. Fish oil administration in older adults : is there potential for adverse events ? A systematic review of the literature. *BMC Geriatr*, 2013, 13 : 41
384. Yee LD et al. ω -3 Fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. *Am J Clin Nutr*, 2010, 91 (5) : 1185–1194
385. Watson JE et al. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. *Prostaglandins Other Lipid Mediat*. 2019 Aug;143:106337
386. Wu Z et al. Omega-3 fatty acid improves the clinical outcome of hepatectomized patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma. *J Biomed Res*, 2012, 26 (6) : 395–399

Huile d'olive et cancers

387. Fortes C et al. Evaluation of the anti-angiogenic potential of hydroxytyrosol and tyrosol, two bio-active phenolic compounds of extra virgin olive oil, in endothelial cell cultures. *Food Chem*, 2012, 134 : 134–140
388. Hernández Á, Estruch R. The Mediterranean Diet and Cancer: What Do Human and Molecular Studies Have to Say about It? *Nutrients*. 2019 Sep 9;11(9). pii: E2155
389. Psaltopoulou T et al. Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of

13800 patients and 23340 controls in 19 observational studies. *Lipids Health Dis*, 2011 ; 10: 127

Fibres et cancers

390. <https://www.lanutrition.fr/les-news/contre-le-cancer-du-sein-faites-le-plein-de-fibres>
391. Barnard RJ et al. Effects of a low-fat, high-fiber diet and exercise program on breast cancer risk factors in vivo and tumor cell growth and apoptosis in vitro. *Nutr Cancer*, 2006;55:28–34
392. Breneman CB and Tucker L. Dietary fibre consumption and insulin resistance—the role of body fat and physical activity. *Br J Nutr*, 2013;110(2):375–383
393. Farvid MS et al. Dietary Fiber Intake in Young Adults and Breast Cancer Risk. *Pediatrics*, 2016 Mar;137(3):1-11.
394. Gerber M. Fiber and breast cancer: another piece of the puzzle—but still an incomplete picture. *J Natl Cancer Inst*, 1996;88(13):857–858
395. Jia-Yi D et al. Dietary fiber intake and risk of breast cancer: a meta-analysis of prospective cohort studies. *Am J Clin Nutr*, first published July 20, 2011.
396. Ma Y et al. Single-component versus multicomponent dietary goals for the metabolic syndrome: a randomized trial. *Ann Intern Med*, 2015 Feb 17;162(4):248-57.
397. Maino Vieytes CA et al. Dietary Fiber, Whole Grains, and Head and Neck Cancer Prognosis: Findings from a Prospective Cohort Study. *Nutrients*, 2019 Sep 27;11(10). pii: E2304
398. Oh H. Different dietary fibre sources and risks of colorectal cancer and adenoma: a dose-response meta-analysis of prospective studies. *Br J Nutr*, 2019 Jul 2:1-11
399. Rose DP et al. High-fiber diet reduces serum estrogen concentrations in premenopausal women. *Am J Clin Nutr*, 1991;54(3):520–525
400. Carbohydrate intake, glycemic index and prostate cancer risk. AUA annual meeting. Communication du 20 mai 2014 10h30. Résumé PD31-11. *Prostate Cancer: Epidemiology & Natural History*.

Lignanes, lin et cancers

401. Aberg UW et al. Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. *PLoS ONE*, 2011, 6 (9)
402. Brooks JD et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy. *Am J Clin Nutr*, 2004, 79 (2) : 318-325
403. Buck K et al. Meta-analyses of lignans and enterolignans in relation to breast cancer risk. *Am J Clin Nutr*, 2010, 92 (1) : 141 - 153
404. Buck K et al. Serum enterolactone and prognosis of postmenopausal breast cancer. *J Clin Oncol*, 2011, 29 (28): 3730 - 3738
405. Guglielmini P et al. Serum enterolactone levels and mortality outcome in women with early breast cancer : a retrospective cohort study. *Breast Cancer Res Treat*, 2012, 132 (2) : 661 - 668
406. Haggans CJ et al. The effect of flaxseed and wheat bran consumption on urinary estrogen metabolites in premenopausal women. *Cancer Epidemiol Biomarkers Prev*, 2000, 9 (7) : 719-725
407. McCann SE et al. Dietary lignan intakes in relation to survival among women with breast cancer: the Western New York Exposures and Breast Cancer (WEB) Study. *Breast Cancer Res Treat*, 2010,122 (1) : 229-35
408. Thompson LU et al. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. *Clin. Cancer Res*, 2005, 11 (10) : 3828 – 3835

Phytoestrogènes de soja et cancers

409. Caan BJ et al. Soy food consumption and breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev*, 2011 May ;20(5) :854-8
410. Fritz H et al. Soy, Red Clover, and Isoflavones and Breast Cancer : A Systematic Review. *PLoS One*, 2013, 8 (11) : e81968
411. Guha N et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors : the Life After Cancer Epidemiology study. *Breast Cancer Res Treat*, 2009,118 (2) : 395-405
412. Horakova D et al. Risks and protective factors for triple negative breast cancer with a focus on micronutrients and infections. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, 2018 May 15
413. Ide H et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. *Prostate*, 2010, 70 (10) : 1127-33
414. Kang X et al. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. *CMAJ*, 2010, 182 (17) : 1857–1862
415. Kweon SS et al. Intake of specific nonfermented soy foods may be inversely associated with risk of distal gastric cancer in a Chinese population. *J Nutr*, 2013 ;143 (11) : 1736-42
416. Lee SA et al. Adolescent and adult soy food intake and breast cancer risk : results from the Shanghai Women's Health Study. *Am J Clin Nutr*, 2009 ; 89 (6) : 1920-6
417. Li Y et al. Epigenetic reactivation of estrogen receptor- α (ER α) by genistein enhances hormonal therapy sensitivity in ER α -negative breast cancer. *Mol Cancer*, 2013, 12, 9
418. Li Y et al. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. *Cancer Res*, 2005, 65 (15) : 6934-42
419. Mahmoud AM et al. Soy isoflavones and prostate cancer : a review of molecular mechanisms. *J Steroid Biochem Mol Biol*, 2014; 140 : 116-32
420. Nagaraju GP et al. Pleiotropic effects of genistein in metabolic, inflammatory and malignant diseases. *Nutr Rev*, 2013 Aug ; 71(8) :562-72

421. Nagata C et al. Factors to consider in the association between soy isoflavone intake and Breast Cancer risk. *J Epidemiol*, 2010, 20 (2): 83–89
422. Park SY et al. Legume and isoflavone intake and prostate cancer risk: The Multiethnic Cohort Study. *Int J Cancer*, 2008; 123(4): 927–932.
423. Pudenz M et al. Impact of soy isoflavones on the epigenome in cancer prevention. *Nutrients*, 2014; 6 (10) : 4218-72
424. Sarkar FH et al. Soy isoflavones and cancer prevention. *Cancer Invest*, 2003; 21 (5) : 744-57
425. Shu XO et al. Soy food intake and breast cancer survival. *JAMA*, 2009, 302 (22) : 2437-43.
426. Vaishampayan U et al. Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutr Cancer*, 2007, 59 (1)
427. Wu AH et al. Epidemiology of soy exposures and breast cancer risk. *Br J Cancer*, 2008 Jan 15 ;98(1) :9-14

Nutriments et cancers

428. Ames BN. Prevention of mutation, cancer and other age-associated diseases by optimizing micronutrient intake. *J Nucleic Acids*, 2010 Sep 22:2010, 725071
429. Mokbel K et al. Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. *Anticancer Res*, 2019 Oct;39(10):5231-5259

Vitamine C et cancers

430. Carr AC et al. Intravenous Vitamin C for Cancer Therapy – Identifying the Current Gaps in Our Knowledge. *Front Physiol*, 2018, 9 : 1182
431. Carr AC et al. Relief from cancer chemotherapy side effects with pharmacologic vitamin C. *N Z Med J*, 2014, 127 (1388) : 66-70
432. Du J et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. *Clin Cancer Res*, 2010, 16 (2) : 509–520.
433. Fritz H et al. Intravenous Vitamin C and Cancer : a Systematic Review. *Integr Cancer Ther*, 2014, 13 (4) : 280-300
434. Harris HR et al. Vitamin C and survival among women with breast cancer : a meta-analysis. *Eur J Cancer*, 2014 May, 50 (7) : 1223-31
435. Harris HR et al. Vitamin C intake and breast cancer mortality in a cohort of Swedish women. *Br J Cancer*, 2013, 109 (1) : 257-64
436. Holm LE et al. Treatment failure and dietary habits in women with breast cancer. *J Natl Cancer Inst*, 85 : 32-36, 1993
437. Ingram D. Diet and subsequent survival in women with breast cancer. *Br J Cancer*, 69 : 592-595, 1994
438. Jain M et al. Premorbid diet and the prognosis of women with breast cancer. *J Natl Cancer Inst*, 86:13901397, 1994
439. Jenab M et al. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Carcinogenesis*, 2006 ; 27(11) : 2250-7
440. Mikirova N et al. Effect of high-dose intravenous vitamin C on inflammation in cancer patients. *J Transl Med*, 2012, 10 : 189
441. Mikirova N et al. Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. *Journal of Translational Medicine*, 2013, 11 : 191
442. Moertel CG et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. *N Engl J Med*, 1985, 312 (3) : 137-41
443. Monti DA et al. Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer. *PLoS One*. 2012, 7 (1) : e29794
444. Rohan TE et al. Dietary factors and survival from breast cancer. *Nutr Cancer*, 20 :167-177, 1993

Magnésium et cancers

445. Dai Q et al. The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. *Am J Clin Nutr*, 2007, 86 (3) : 743–751.
446. Dai Q et al. Blood Magnesium and the Interaction with Calcium on the Risk of High-Grade Prostate Cancer. *PLoS One*, 2011, 6 (4) : e18237
447. Deng X et al. Magnesium, vitamin D status and mortality : results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. *BMC Med*, 2013, 11 : 187
448. Mahabir S et al. Dietary magnesium and DNA repair capacity as risk factors for lung cancer. *Carcinogenesis*, 2008, 29 (5) : 949–956

Zinc et cancers

449. Epstein MM et al. Dietary zinc and prostate cancer survival in a Swedish cohort. *Am J Clin Nutr*, 2011; 93 (3) : 586-93
450. Ho E et al. Zinc deficiency, DNA damage and cancer risk. *Nutr Biochem*, 2004, 15 (10) : 572-8
451. Kolenko V et al. Zinc and zinc transporters in prostate carcinogenesis. *Nat Rev Urol*, 2013, 10(4) : 219–226.
452. Zhang X et al. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. *Cancer Causes Control*, 2011 ; 22 (12) : 1627–1637

Folates et cancers

453. Chiang FF et al. High serum folate might have a potential dual effect on risk of colorectal cancer. *Clin Nutr*, 2014 Nov 8
454. Lee JE et al. Folate intake and risk of colorectal cancer and adenoma: modification by time. *Am J Clin Nutr*, 2011 Apr;93(4):817-25
455. Liu Y et al. Vitamin and multiple-vitamin supplement intake and incidence of colorectal cancer: a meta-analysis of cohort studies. *Med Oncol*, 2015 Jan; 32 (1) : 434

456. Piyathilake CJ et al. Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. *Cancer Prev Res (Phila)*, 2014, 7 (11) : 1128-37
457. Zhang YF et al. Folate intake and the risk of breast cancer : a dose-response meta-analysis of prospective studies. *PLoS One*, 2014, 9 (6) : e100044
458. Tio M et al. Folate intake and the risk of prostate cancer : a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*, 2014, 17(3) : 213-9
459. Wien TN et al. Cancer risk with folic acid supplements : a systematic review and meta-analysis. *BMJ Open*, 2012; 2 (1) : e000653

Vitamine D et cancers

460. Bhatia V et al. Restoration of the anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D by silibinin in vitamin D-resistant colon cancer cells. *Cancer Lett*, 2015 Apr, Pii : S0304-3835 (15) 00244-X
461. Bjelakovic G et al. Vitamin D supplementation for prevention of mortality in adults. *Cochrane Database Syst Rev*, 2014 Jan 10;(1):CD007470
462. Blutt SE, Weigel NL. Vitamin D and prostate cancer. *Proc Soc Exp Biol Med*, 1999, 221 (2) : 89–98
463. Brosseau C et al. Role of Insulin-Like Growth Factor Binding Protein-3 in 1, 25-Dihydroxyvitamin-D3-Induced Breast Cancer Cell Apoptosis. *Int J Cell Biol*, 2013, 2013 : 960378
464. Danilenko M et al. Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. *Exp Cell Res.*, 2004, 298 (2) : 339-58.
465. Deeb KK et al. Vitamin D signalling pathways in cancer : potential for anticancer therapeutics. *Nat Rev Cancer*, 2007 Sep, 7(9) :684-700
466. Feskanich D et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev*, 2004 ; 13 (9) : 1502–1508
467. Garland CF et al. Vitamin D and prevention of breast cancer : pooled analysis. *J Steroid Biochem Mol Biol*, 2007 ; 103 (3–5) : 708–711
468. Garland CF et al. The Role of Vitamin D in Cancer Prevention. *Am J Public Health*, 2006, 96 (2) : 252–261 Grant WB et al, Ecological studies of the UVB-vitamin D-cancer hypothesis, *Anticancer Res*, 2012, 32 (1) : 223-36
469. Gewirtz DA et al. Vitamin D3 and vitamin D3 analogues as an adjunct to cancer chemo-therapy and radiotherapy. *Curr Med Chem Anticancer Agents*, 2002, 2 (6) : 683-90
470. Karthikayan A et al. Low serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and poor prognostic factors in patients with breast carcinoma. *Arch Endocrinol Metab*, 2018 Aug, 62 (4) : 452-459
471. Krishnan AV et al. Vitamin D and breast cancer : inhibition of estrogen synthesis and signaling. *J Steroid Biochem Mol Biol*, 2010, 121 (1-2) : 343-8
472. Ma Y et al. Mechanistic insights of vitamin D anticancer effects. *Vitam Horm*, 2016 ; 100 :395-431
473. Ma Y et al. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy. *Cancer Biomark*, 2017 ; 18(3) :297-303
474. Marwan GF et al. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. *Int J Colorectal Dis*, 2009, 24 (2) : 219–224
475. Revuelta IR et al. Systematic review and meta-analysis : prevalence and possible causes of vitamine D deficiency and insufficiency in pediatric cancer patients. *Clin Nut*, 2015 Jan 16
476. Schöttker B et al. Vitamin D and mortality : meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ*, 2014, 348
477. Trump DL et al. Vitamin D compounds : clinical development as cancer therapy and prevention agents. *Anticancer Res.*, 2006, 26 (4A) : 2551-6
478. Viala M et al. Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer : a retrospective study. *BMC Cancer*, 2018, 18 (1) : 770
479. Wahler J et al. Vitamin D compounds reduce mammosphere formation and decrease expression of putative stem cell markers in breast cancer. *J Steroid Biochem Mol Biol*, 2015 Apr, 148 : 148-55
480. Wong GL et al. Adverse effects of vitamin D deficiency on outcomes of patients with chronic hepatitis B. *Clin Gastroenterol Hepatol*, 2015 Apr, 13 (4) : 783-790. e1
481. Zeichner SB et al. Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. *Clin Breast Cancer*, 2015, 15 (1) : e1-11

Vitamine K2 et cancers

482. Habu D et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. *JAMA*, 2004, 292 (3) : 358-61
483. Juanola-Falgarona M et al. Dietary Intake of Vitamin K Is Inversely Associated with Mortality Risk. *J Nutr*, 2014, May 1, 113, 187740
484. Kakizaki S et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. *J Gastroenterol Hepatol*, 2007, 2 (4) : 518-22
485. Nimptsch K et al. Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). *Am J Clin Nutr*, 2008, 87, (4) : 985–92

Microbiote et cancers

486. Voir 11 De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol*, 2019 January 14; 25(2): 151-162
487. <https://netcancer.net/publications/le-microbiote-intestinal-un-nouvel-acteur-en-oncologie/> Consulté pour la dernière fois en octobre 2019.
488. <https://netcancer.net/actualites/effet-du-microbiote-sur-la-reponse-a-limmunotheapie-pr-ghiringhelli/> Consulté pour la dernière fois en octobre 2019.
489. <https://www.biocodexmicrobiotainstitute.com/les-microbiotes> Consulté pour la dernière fois en octobre 2019.
490. Blander JM et al. Regulation of inflammation by microbiota interactions with host. *Nat Immunol*, 2017 Jul 19 ; 18(8) :851-860
491. Bultman SJ. Emerging roles of the microbiome in cancer. *Carcinogenesis*, 2014 Feb ; 35(2) : 249-55
492. Arkan MC. The intricate connection between diet, microbiota and cancer : A jigsaw puzzle. *Semin Immunol.*, 2017 Sep 1, pii : S1044-5323(17)30023-4
493. Bultman SJ. The microbiome and its potential as a cancer preventive intervention. *Semin Oncol*, 2016 Feb ; 43 (1) : 97-106
494. De Almeida CV et al. Role of diet and gut microbiota on colorectal cancer. Immunomodulation. *World J Gastroenterol*, 2019 January 14; 25(2): 151-162.
495. Gopalakrishnan V et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. *Cancer cell*, 2018
496. Kostic AD et al. *Fusobacterium nucleatum* potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. *Cell Host Microbe*, 2013.
497. Iida N et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science*, 2013.
498. Liu F et al. Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer. *Int J Biol Sc*, 2019 Sep 7;15(11):2381-2392
499. Matson V et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. *Science*, 2018.
500. Paulos CM et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *Journal of Clinical Investigation*, 2007.
501. Pedersen et al. The Human Intestinal Microbiome in Health and Disease. *The new england journal of medicine*, 2016.
502. Redman MG et al. The efficacy and safety of probiotics in people with cancer : a systematic review. *Ann Oncol*, 2014 May 11,
503. Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. *Science*, 2018.
504. Roy S et al. Microbiota : a key orchestrator of cancer therapy. *Nat Rev Cancer*, 2017 May ; 17(5) :271-285
505. Rubinstein MR et al. *Fusobacterium nucleatum* promotes colorectal carcinogenesis by modulating E-cadherin/ β -catenin signaling via its FadA adhesin. *Cell Host Microbe*, 2013.
506. Sivan A et al. Commensal *Bifidobacterium* promotes antitumor immunity and facilitates anti-PD-L1 efficacy. *Science*, 2015.
507. Sommer F. and Backhed F. The gut microbiota-masters of host development and physiology. *Nature reviews Microbiology*, 2013.
508. Song M et al. Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer. *Gastroenterology*, 2019 Oct 3. pii: S0016-5085(19)41369-3
509. Vetzou M et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*, 2015.
510. Viennois E et al. Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention? *Cell Mol Gastroenterol Hepatol*, 2019;8(1):61-71
511. Vlaud S et al, The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide, *Science*, 2013
512. Zeller G et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology*, 2014.
513. Wallace BD et al. Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. *Science*, 2010.

Quelles sont les pistes de solutions ? Zoom sur les bonnes pratiques

Le jeûne dans le traitement des cancers

514. Bauersfeld SP et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer : a randomized cross-over pilot study. *BMC Cancer*, 2018, 18 (1) : 476
515. Brandhorst S et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance and healthspan. *Cell Metab*, 2015, 22 (1) : 86–99
516. Cheng CW et al. Prolonged Fasting reduces IGF-1/PKA to promote hematopoietic stem cell-based regeneration and reverse immunosuppression. *Cell Stem Cell*, 2014, 14 (6) : 810–823.
517. de Groot S et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients : a randomized pilot study. *BMC Cancer*, 2015, 15 : 652
518. Fontana L et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. *Aging Cell*, 2008,7 (5) : 681-7
519. Kogevinas M et al. Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study). *Int J Cancer*, 2018 Jul 17
520. Lee C et al. Starvation, detoxification, and multidrug resistance in cancer therapy. *Drug Resist Updat*, 2012, 15 (1-2) : 114–122.
521. Marinac CR et al. Prolonged Nightly Fasting and Breast Cancer Prognosis. *JAMA Oncol.*, 2016, 2 (8) : 1049-55
522. Safdie FM et al. Fasting and cancer treatment in humans : a case series report. *Aging (Albany NY)*, 2009, 1 (12) : 988–1007

Sarcopénie et cancers

523. An JM et al. Dietary intake of probiotic kimchi ameliorated IL-6-driven cancer cachexia. *J Clin Biochem Nutr*, 2019 Sep;65(2):109-117
524. Barret M et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. *NutrCancer*, 2014 ; 66 (4) : 583-9
525. Gonzalez MC et al. Obesity paradox in cancer : new insights provided by body composition. *Am J Clin Nutr*, 2014 ; 99 (5) : 999-1005
526. Kidd AC et al. Cancer cachexia in thoracic malignancy: a narrative review. *Curr Opin Support Palliat Care*, 2019 Oct 4

Les troubles du sommeil, la mélatonine et cancers

527. Bae SA et al. At the interface of lifestyle, behaviour and circadian rhythms: metabolic implications. *Front Nutr*. 2019 Aug 28;6:132
528. Blask DE. Melatonin, sleep disturbance and cancer risk. *Sleep Med Rev*, 2009 , 13 : 257-64
529. Caplan LS et al. Breast cancer and electromagnetic fields – a review. *Ann Epidemiol*, 2000; 10 (1) : 31-44
530. Gassmann AS et al. Have female flight attendants an over-risk of breast cancer? *Gynecol Obstet Fertil*, 2014 Oct 31
531. Jia Y et al. Does night work increase the risk of breast cancer ? A systematic review and meta-analysis of epidemiological studies. *Cancer Epidemiol*, 2013; 37 (3) : 197-206
532. Kakizaki M et al. Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. *Br J Cancer*, 2008, 99 : 1502-5.
533. Kolstad HA. Nightshift work and risk of breast cancer and other cancers-a critical review of the epidemiologic evidence. *Scand J Work Environ Health*, 2008, 34 : 5-22.
534. Lissoni P et al. Is there a role for melatonin in supportive care? *Support Care Cancer*, 2002; 10 (2) : 110-6
535. Megdal SP et al. Night work and breast cancer risk : a systematic review and meta-analysis. *Eur J Cancer*, 2005; 41 (13) : 2023-32
536. Rafnsson V et al. Risk of breast cancer in female flight attendants : a population-based study (Iceland). *Cancer Causes Control*, 2001;12 (2) : 95-101
537. Thompson CL et al. Short duration of sleep increases risk of colorectal adenoma. *Cancer*, 2010, 117 : 841-7
538. Verkasalo PK et al. Sleep duration and breast cancer : a prospective cohort study. *Cancer Res*, 2005, 65 : 9595.
539. Viswanathan AN et al. Night shift work and the risk of endometrial cancer. *Cancer Res*, 2007, 67: 10618
540. Wu AH et al. Sleep duration, melatonin and breast cancer among Chinese women in Singapore. *Carcinogenesis*, 2008, 29 : 1244-8.

Stress et cancers

541. Antonova L et al. Stress and breast cancer : from epidemiology to molecular biology. *Breast Cancer Res*, 2011; 13 (2)
542. Moreno-Smith M et al. Impact of stress on cancer metastasis. *Future Oncol*, 2010; 6 (12) : 1863-1881
543. Pudrovskaya T et al. Higher-Status Occupations and Breast Cancer : A Life-Course Stress Approach. *Soc Sci Med*, 2013; 89: 53-61
544. Wirth M et al. The Epidemiology of Cancer Among Police Officers. *Am J Ind Med*, 2013; 56 (4) : 439-453

Exercices/Activités physiques et cancers

545. Davies NJ et al. The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship : a review of the literature. *Br J Cancer*, 2011, 105 (Suppl 1) : S52-S73
546. Luan X et al. Exercise as a prescription for patients with various diseases. *J Sport Health Sci*, 2019 Sep;8(5):422-441
547. Pekmezci DW et al. Updated evidence in support of diet and exercise interventions in cancer survivors. *Acta Oncol*, 2011, 50 (2) : 167-78
548. Schmidt T et al. Physical activity influences the immune system of breast cancer patients. *J Cancer Res Ther*, 2017 Jul-Sep ; 13(3) :392-398

Quelques Contre-indications

549. <https://www.cancer.be/complementsalimentaires/20475>
550. Vogel J. et al. Handboek voeding bij kanker, Utrecht: de Tijdstroom, 2012.
551. www.bcfi.be